Hei · 2022 · Schizophrenia bulletin open
Trial comparing cognition in early schizophrenia
Would adding a supplement containing glucoraphanin and its conversion enzyme affect cognition in early schizophrenia?
Human · randomized double-blind controlled trial
Key findings
Overall cognitive and symptom assessments
The primary MATRICS cognitive composite score and PANSS symptom score showed no significant between-group differences.
Individual cognitive domains
Improvements were observed in spatial working memory (p=0.004) and verbal learning (p=0.031). Reasoning and problem solving (p=0.063) were not significant.
Study design
At four centers in China, 172 participants were assigned to two dose groups or placebo. At least one follow-up assessment was obtained from 151 participants. MATRICS cognition and PANSS symptoms were evaluated over 22 weeks.
- Participants
- China · 172 people with early schizophrenia
151 with follow-up · three groups - Intake and observation
- Glucoraphanin + conversion enzyme
4 or 6 research tablets/day
22 weeks · added to usual treatment - Measures
- MATRICS composite and domain scores
Study context
The primary cognitive composite score was not significant. Differences were observed in two secondary measures, spatial working memory and verbal learning.
Observed during intake: The study reported generally good tolerability.
Original paper and sources
Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial.
- Journal
- Schizophrenia bulletin open · 2022 · 3(1): sgac024
- First published
- 2022-01-01